.Attributes Medication, Posted online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint requires incorporation of people with MASLD as well as size of liver end results in cardio-- kidney-- metabolic trials, when data recommend mechanistically possible benefits and also clinical protection-- as well as summarizes considerations for test layout as well as regulative approval.